Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | CLPP | Q16740 | 3/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.33 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.33 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3987185 | 0.90 | SMN1; SMN2 (0.40) | KCNH2GRM2FAAHMGLLMAPK14 | |
| SCHEMBL3991527 | 0.89 | P2RX7 (0.36) | P2RX7 | |
| SCHEMBL3987007 | 0.89 | SCD (0.38) | SCDDRD4PTGER4GRM2FSCN1 | |
| SCHEMBL3985667 | 0.89 | SCD (0.39) | SCDDRD4PTGER4GRM2FSCN1 | |
| SCHEMBL3983704 | 0.87 | SCD (0.36) | SCDDRD4PTGER4GRM2FSCN1 | |
| SCHEMBL3983623 | 0.85 | SCD (0.38) | SCDPTGER4FSCN1 | |
| SCHEMBL3985359 | 0.84 | SCD (0.33) | SCDDRD4PDE4APDE4BPDE4C | |
| SCHEMBL3989255 | 0.83 | MAOB (0.35) | PTGER4FSCN1P2RX7 | |
| SCHEMBL4746270 | 0.83 | SCD (0.40) | SCDDRD4FSCN1P2RX7MAPK14 | |
| SCHEMBL3981450 | 0.81 | SMN1; SMN2 (0.43) | FAAHMGLLMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756114-B1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-11-19 | — | — | EP | disclosed |
| US-7538112-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080287394-A1 | Hiv Integrase Inhibitors | MERCK & CO., INC. (US) | 2008-11-20 | — | — | US | disclosed |
| EP-1756114-A2 | HIV INTEGRASE INHIBITORS | Merck and Co., Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005110414-A2 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287394-A1 | Hiv Integrase Inhibitors | DHPS, DPYD, TYMP | SCD 2672/4885DRD4 618/4885CLPP 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.